These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 12407835)

  • 21. [Inotropic agents].
    Yasumura Y
    Nihon Rinsho; 2006 May; 64(5):927-33. PubMed ID: 16689376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Elderly heart failure patients and the role of beta-blocker therapy].
    Middeljans-Tijssen CW; Jansen RW
    Tijdschr Gerontol Geriatr; 2006 Apr; 37(2):67-77. PubMed ID: 16704019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. beta-Blocker therapy for congestive heart failure: clinical considerations.
    Kamath SA; Yancy CW
    Postgrad Med; 2005 Dec; 118(6 Suppl Beta-Blockers):12-20. PubMed ID: 19667706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beta-blocker therapy in heart failure in the elderly.
    Fu M
    Int J Cardiol; 2008 Apr; 125(2):149-53. PubMed ID: 18023898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits of inpatient initiation of beta-blockers.
    Ventura HO
    Am Heart J; 2004 Dec; 148(6):944-50. PubMed ID: 15632876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An overview of inotropic agents.
    Vroom MB
    Semin Cardiothorac Vasc Anesth; 2006 Sep; 10(3):246-52. PubMed ID: 16959760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of congestive heart failure: is the role of positive inotropic therapy fading?
    Futterman LG; Lemberg L
    Am J Crit Care; 1996 Nov; 5(6):455-60. PubMed ID: 8922162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levosimendan: current status and future prospects.
    Archan S; Toller W
    Curr Opin Anaesthesiol; 2008 Feb; 21(1):78-84. PubMed ID: 18195615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. beta-Blocker therapy in heart failure.
    Doughty RN
    Heart Fail Monit; 2000; 1(1):2-7. PubMed ID: 12634875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker).
    Dimopoulos K; Salukhe TV; Coats AJ; Mayet J; Piepoli M; Francis DP
    Int J Cardiol; 2004 Feb; 93(2-3):105-11. PubMed ID: 14975535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability to beta-blocker therapy among heart failure patients in clinical practice.
    Butler J; Khadim G; Belue R; Chomsky D; Dittus RS; Griffin M; Wilson JR
    J Card Fail; 2003 Jun; 9(3):203-9. PubMed ID: 12815570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Why do patients fail to receive beta-blockers for chronic heart failure over time? A "real-world" single-center, 2-year follow-up experience of beta-blocker therapy in patients with chronic heart failure.
    Parameswaran AC; Tang WH; Francis GS; Gupta R; Young JB
    Am Heart J; 2005 May; 149(5):921-6. PubMed ID: 15894978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Digoxin in patients with heart failure.
    Böhm M
    N Engl J Med; 1997 Jul; 337(2):129-30; author reply 130-1. PubMed ID: 9221339
    [No Abstract]   [Full Text] [Related]  

  • 35. Evolving concepts in the treatment of heart failure: should new inotropic agents carry promise or paranoia?
    Young JB
    Pharmacotherapy; 1996; 16(2 Pt 2):78S-84S. PubMed ID: 8668609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
    Pitt B; Fonarow GC; Gheorghiade M; Deedwania PC; Duprez DA
    Am J Cardiol; 2006 May; 97(10A):26F-33F. PubMed ID: 16698332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical experience with levosimendan in anesthesiology and in the intensive care unit.
    Cavana M; Pignataro C; Fraticelli A; Mebazaa A
    Ital Heart J; 2003 May; 4 Suppl 2():61S-64S. PubMed ID: 14635372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
    Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M
    Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.